CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Exclusion Criteria

• •Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or temsirolimus) or CB-839
• •Receipt of any anticancer therapy within the following windows before randomization:
• •* TKI therapy within 2 weeks or 5 half-lives, whichever is longer
• •* Any type of anti-cancer antibody within 4 weeks
• •* Cytotoxic chemotherapy within 4 weeks
• •* Investigational therapy within 4 weeks or 5 half-lives, whichever is longer
• •Unable to receive medications orally (PO) or any condition that may prevent adequate absorption of oral study medication
• •Major surgery within 28 days prior to randomization
• •Requirement for continued proton pump inhibitor after randomization
• •Chronic treatment with corticosteroids or other immunosuppressive agents except (i) inhaled or topical steroids or replacement dose corticosteroids equivalent to ≤ 10 mg prednisone and (ii) patients receiving physiological doses of hydrocortisone for adrenal insufficiency